N@N

Pluristem Therapeutics Inc (NASDAQ:PSTI), Up By 5.84% ($0.18) From $3.080 After BUYINS.NET Report Predicted Stock Would Go Up D

^{Published on 2012-12-31 07:47:02 - WOPRAI}
 

December 31, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Friday, December 28th 2012 stating that Pluristem Therapeutics Inc (NASDAQ:PSTI) was expected to go Up due to the Bullish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=psti&id=337528

At the time this story was written, Pluristem Therapeutics Inc (NASDAQ:PSTI) is Up By $0.18 (5.84%) since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.

The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

Pluristem Therapeutics Inc (NASDAQ:PSTI) - Pluristem Therapeutics Inc., a bio-therapeutics company, engages in the research, development, and commercialization of standardized cell therapy products and related technologies for the treatment of life threatening diseases. The company s products are derived from human placenta that is a non-controversial, non-embryonic, and adult cell source. Its Placental adherent stromal cells are grown in the company's proprietary PluriX three-dimensional process that allows cells to grow in a natural environment. The company develops placenta expanded cells (PLX) and peripheral artery disease cells, an allogeneic therapeutic product that is in Phase-II clinical trials for the treatment of intermittent claudication, critical limb ischemia, and Buerger's disease. Its PLX product is developed for the treatment of muscle injury, bone marrow diseases, inflammatory bowel disease, and multiple sclerosis, as well as for pulmonary disorders, acute radiation syndrome, acute myocardial infarction, diabetic diastolic heart failure, neuropathic pain, inflammatory bowel disease, multiple sclerosis, and ischemic stroke for which the product is in various pre-clinical trials. Pluristem Therapeutics Inc. is also involved in the development and commercialization of a PLX cell-based product for the treatment of pulmonary arterial hypertension through its license agreement with the United Therapeutics Corporation. The company was formerly known as Pluristem Life Systems Inc. and changed its name to Pluristem Therapeutics Inc. in November 2007. Pluristem Therapeutics Inc. was founded in 2001 and is headquartered in Haifa, Israel..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net